Arcturus Therapeutics Holdings Inc
$ 8.04
5.79%
04 Jun - close price
- Market Cap 231,364,000 USD
- Current Price $ 8.04
- High / Low $ 8.19 / 7.58
- Stock P/E N/A
- Book Value 6.73
- EPS -2.83
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.37 %
- 52 Week High 24.17
- 52 Week Low 5.85
About
Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. The company is headquartered in San Diego, California.
Analyst Target Price
$19.89
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-03 | 2025-11-10 | 2025-08-11 | 2025-05-12 | 2025-03-06 | 2024-11-07 | 2024-08-05 | 2024-05-08 | 2024-03-07 | 2023-11-14 | 2023-08-07 |
| Reported EPS | -0.95 | -1.03 | -0.49 | -0.34 | -0.52 | -1.11 | -0.26 | -0.64 | -1 | -0.32 | -0.61 | -1.98 |
| Estimated EPS | -1.0133 | 4.28 | 5.53 | 3.21 | -1.19 | -0.4943 | -1.22 | -1.6 | -1.19 | -0.99 | -1.69 | -0.21 |
| Surprise | 0.0633 | -5.31 | -6.02 | -3.55 | 0.67 | -0.6157 | 0.96 | 0.96 | 0.19 | 0.67 | 1.08 | -1.77 |
| Surprise Percentage | 6.2469% | -124.0654% | -108.8608% | -110.5919% | 56.3025% | -124.56% | 78.6885% | 60% | 15.9664% | 67.6768% | 63.9053% | -842.8571% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARCT
2026-05-30 01:58:00
Arcturus Therapeutics Holdings Inc. (ARCT) is showing a mid-channel oscillation pattern, with near-term strong sentiment challenging persistent mid and long-term weakness. AI models have generated three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss levels. The article highlights an exceptional 225.5:1 risk-reward setup, targeting a 75.0% gain versus 0.3% risk.
2026-05-29 23:39:27
Arcturus Therapeutics is drawing significant Wall Street attention due to its innovative self-amplifying mRNA platform and promising pipeline candidates, ARCT-032 for cystic fibrosis and ARCT-810 for OTC deficiency, which are nearing critical clinical and regulatory milestones in early 2026. Analysts project a potential upside of 218% to 404%, with a high target of 775% to 963%, driven by these advancements. However, investing in ARCT is considered high-risk due to the volatility inherent in biotech, relying heavily on successful clinical trial outcomes and regulatory approvals.
2026-05-27 04:10:13
Arcturus Therapeutics Holdings Inc. announced it will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 9:20 a.m. ET. The company, known for its mRNA medicines, focuses on liver and respiratory rare disease therapeutics and has developed the first approved self-amplifying mRNA COVID vaccine, KOSTAIVE®. A webcast of the presentation will be available on Arcturus's investor relations website.
2026-05-26 16:01:00
Arcturus Therapeutics Holdings Inc. announced it will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 9:20 a.m. ET. The company, a messenger RNA medicines specialist, focuses on developing therapeutics for liver and respiratory rare diseases and also manufactures vaccines. Arcturus utilizes advanced technologies like LUNAR® lipid-mediated delivery and STARR® mRNA technology.
2026-05-22 13:39:00
Arcturus Therapeutics is facing challenges with its collaboration with CSL regarding the KOSTAIVE Covid-19 vaccine, with CSL writing off $430 million related to the agreement and arbitration ongoing over milestone payments. This situation creates strategic opportunities for Arcturus to pivot towards new collaboration partners like Sanofi or BioNTech, who are looking to advance their mRNA vaccine pipelines. Despite current low investor confidence and declining revenue from the CSL agreement, Arcturus possesses valuable advanced RNA technology and a pipeline including rare disease programs, which could significantly increase its market capitalization through new partnerships.
2026-05-19 00:50:00
This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, highlighting weak sentiment across all time horizons and an exceptional 232.5:1 risk-reward setup. It outlines three trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis for support and resistance levels. The report emphasizes the potential for a 74.3% gain against a 0.3% risk based on current signals.
